
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a promising oncology-focused biopharmaceutical company with a diverse portfolio and strong market position. Their lead asset BRUKINSA has shown growth and potential for future success, leading analysts to maintain a BUY rating. The company's revenue is expected to increase due to the success of BRUKINSA and new market expansion, and upcoming catalysts point to potential for future growth.
Bears say
BeOne Medicines is currently facing material sustainability issues such as implementing green manufacturing processes, data transparency, and socially responsible drug pricing. These issues can potentially affect the company's financial performance and hinder its growth potential. Additionally, the company's financial results for the first quarter of 2026 exceeded expectations, however, its financial guidance for the full year was only slightly increased and may not be enough to sustain the company's growth and address its sustainability concerns. With these factors in mind, a negative outlook on BeOne Medicines stock may be warranted as the company's future success and potential may be limited by its sustainability challenges and cautious financial outlook.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares